The New England journal of medicine, 2019-12, Vol.381 (25), p.2391-2402
- González-Martín, Antonio
- Pothuri, Bhavana
- Vergote, Ignace
- DePont Christensen, René
- Graybill, Whitney
- Mirza, Mansoor R
- McCormick, Colleen
- Lorusso, Domenica
- Hoskins, Paul
- Freyer, Gilles
- Baumann, Klaus
- Jardon, Kris
- Redondo, Andrés
- Moore, Richard G
- Vulsteke, Christof
- O’Cearbhaill, Roisin E
- Lund, Bente
- Backes, Floor
- Barretina-Ginesta, Pilar
- Haggerty, Ashley F
- Rubio-Pérez, Maria J
- Shahin, Mark S
- Mangili, Giorgia
- Bradley, William H
- Bruchim, Ilan
- Sun, Kaiming
- Malinowska, Izabela A
- Li, Yong
- Gupta, Divya
- Monk, Bradley J
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- González-Martín, Antonio
- Pothuri, Bhavana
- Vergote, Ignace
- DePont Christensen, René
- Graybill, Whitney
- Mirza, Mansoor R
- McCormick, Colleen
- Lorusso, Domenica
- Hoskins, Paul
- Freyer, Gilles
- Baumann, Klaus
- Jardon, Kris
- Redondo, Andrés
- Moore, Richard G
- Vulsteke, Christof
- O’Cearbhaill, Roisin E
- Lund, Bente
- Backes, Floor
- Barretina-Ginesta, Pilar
- Haggerty, Ashley F
- Rubio-Pérez, Maria J
- Shahin, Mark S
- Mangili, Giorgia
- Bradley, William H
- Bruchim, Ilan
- Sun, Kaiming
- Malinowska, Izabela A
- Li, Yong
- Gupta, Divya
- Monk, Bradley J
- Titel
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- Ist Teil von
- The New England journal of medicine, 2019-12, Vol.381 (25), p.2391-2402
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients with newly diagnosed advanced ovarian cancer were randomly assigned to receive daily niraparib, a PARP inhibitor, or placebo as maintenance therapy after having had a response to platinum-based chemotherapy. Progression-free survival was significantly longer in the niraparib group than in the placebo group, with some increase in the frequency of myelosuppression and nausea.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1910962Titel-ID: cdi_proquest_miscellaneous_2299141735
- Format
- –
- Schlagworte
- Adenosine, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents - therapeutic use, Breast cancer, Cancer therapies, Chemotherapy, Combined Modality Therapy, Double-Blind Method, Double-blind studies, Female, Homologous recombination, Humans, Indazoles - adverse effects, Indazoles - therapeutic use, Maintenance Chemotherapy, Medical diagnosis, Middle Aged, Mutation, Nausea - chemically induced, Neutropenia, Ovarian cancer, Ovarian Neoplasms - drug therapy, Ovarian Neoplasms - mortality, Ovarian Neoplasms - surgery, Patients, Piperidines - adverse effects, Piperidines - therapeutic use, Platinum, Poly(ADP-ribose) polymerase, Poly(ADP-ribose) Polymerase Inhibitors - adverse effects, Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use, Population, Progression-Free Survival, Quality of Life, Questionnaires, Ribose, Survival, Survival Analysis, Thrombocytopenia, Tumors